drugset / Trial / NCT05341089

A Study of Two Different Formulations of LY3502970 in Healthy Participants

NCT05341089

Phase 1 Completed 39 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.

Timeline

Start
2022-05-17
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Orforglipron Small molecule 16 mg Oral

Indications

No indication recorded.